Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD)NORTH CHICAGO, Ill., June 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. ("Celsius"), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius' lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibod ...

Allē Members Enjoy the Aesthetic Treatments They Love Today, and Pay Over-Time with No Hard Credit Checks Participation Comes at No Cost* to Aesthetic Providers for Allergan Aesthetics Treatments and Products, Increasing Affordability of Treatments with Flexible Payment Options IRVINE, Calif., June 27, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today debuted Allē Payment Plans, powered by Cherry. By giving consumers the power to pay over-time for aesthetic treatments and pr ...

Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neurological diseases, resulting in a payment of US$10 million to Nxera. Nxera and AbbVie entered into this multi-target collaboration in 2022 to leverage Nxera’s NxWave™ platform to discover, develop and commercialize new medicines targeting novel G protein-coupled receptor (GPCR) targets assoc ...

-  EPKINLY is now the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL)-  Bispecific antibodies are designed to induce targeted cell killing by engaging the immune system-  FL is considered incurable with current standard of care therapies. Many people living with FL who have relapsed or are refractory to existing therapies have limited treatment options and reduced survival1NORTH CHICAGO, ...

AbbVie (ABBV) announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA) seeking approval for ABBV-951 for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). This is the second CRL issued for ABBV-951 by the FDA.The latest CRL was based on some observations on inspection of one of AbbVie's third-party manufacturing facilities listed in the NDA. The inspection did not involve ABBV-951 or any other AbbVie drug. The FDA has not requ ...

The most recent trading session ended with AbbVie (ABBV) standing at $170.75, reflecting a -1.15% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 0.09%. Meanwhile, the Dow lost 0.1%, and the Nasdaq, a tech-heavy index, added 0.16%.Heading into today, shares of the drugmaker had gained 9.98% over the past month, outpacing the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83% in that time.Investors will be eagerly watching for the per ...

U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspection that did not involve ABBV-951 at one of AbbVie's third-party manufacturing facilitiesThe CRL does not identify any issues related to the safety, efficacy or labeling of ABBV-951, including the device, and does not request that AbbVie conduct additional efficacy or safety trials related to the drug or device-related testingAbbVie continues to work with the FDA to bring ABBV-951 ...

Above-average yields and reliable cash flows make these dividend-paying stocks an income-seeking investor's dream come true.If you're looking to pump up your passive income stream, there are a handful of high-yield dividend stocks that deserve your attention. AbbVie (ABBV 1.38%), Ares Capital (ARCC 0.44%), and Realty Income (O 0.92%) have what it takes to deliver heaps of dividend payments to your portfolio in the years ahead.Whether you're interested in a high yield up front, rapid payout growth, or a litt ...

With the stock market near all-time highs, I’m looking forward to the next market crash. Yes, I want the stock market to fall and fall hard. Why? Because that is when you can go on a shopping spree. All the great companies that are trading at exceptionally high premiums will be suddenly offering discounts. That is when you want to buy.The last market crash was brought on by the pandemic. The S&P 500 lost one-third of its value in just one month. Ouch! Since then, though, the benchmark index has been nothing ...

文章核心观点 - 生物科技行业增长放缓,重点转向慢性疾病如糖尿病、癌症和心脏病的治疗[1][2] - 主要生物科技公司正在开发针对长期患者的治疗方案,成为投资者关注的焦点[2] 公司分析 AbbVie (ABBV) - 最近获得FDA批准的溃疡性结肠炎药物Skyrizi,可能也能治疗克罗恩病[4][5] - 考虑到每100名美国人就有1人患有肠道疾病,ABBV的药物销售前景良好[5] Novo Nordisk (NVO) - 计划在北卡罗来纳州扩大11亿美元的制造能力,以满足其减肥和糖尿病药物的需求[6] - 第一季度收入增长22.4%,净利润增长28.2%,现金储备增加有利于进一步扩张[7] Eli Lilly (LLY) - 其糖尿病和减肥药物Mounjaro和Zepbound销售良好,推动收入同比增长[7] - 新的阿尔茨海默病药物Donanemab获FDA批准,为公司开辟了新的市场[8] - 针对美国670万阿尔茨海默病患者的药物有望为公司带来重大影响[8][9]